Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

By M. Borba, F. Val, V. Sampaio, M. Alexandre, G. Melo, M. Brito, M. P. Mourão, J. Brito-Sousa, D. Baía-da-Silva, M. V. Guerra and 18 more. JAMA Network Open, 2020

804 citations recorded by the source corpus.

Key Points Question How safe and effective are 2 different regimens of chloroquine diphosphate in the treatment of severe coronavirus disease 2019 (COVID-19)? Findings In this phase IIb randomized clinical trial of 81 patients with COVID-19, an unplanned interim analysis recommended by an independent data safety and monitoring board found that a higher dosage of chloroquine diphosphate for 10 days was associated with more toxic effects and lethality, particularly affecting QTc interval prolongation. The limited sample size did not allow the study to show any benefit overall regarding treatment efficacy. Meaning The preliminary findings from the CloroCovid-19 trial suggest that higher dosage of chloroquine should not be recommended for the treatment of severe COVID-19, especially among patients also receiving azithromycin and oseltamivir, because of safety concerns regarding QTc interval prolongation and increased lethality.

Subfields: General Health Professions, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/51fbca4200a657fe38e233e277b0d7f59bbad97a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

  1. J. Magagnoli
  2. James W. Hardin
  3. S. Sutton
  4. T. Cummings
  5. Felipe Pereira
  6. J. Ambati
  7. S. Narendran
  8. C. Fischer

Citations in the corpus